Glycostem and medac GmbH will partner to commercialize Glycostem’s lead product, oNKord®
2 August 2022
Menu
Glycostem and medac GmbH will partner to commercialize Glycostem’s lead product, oNKord®
GlycoMscan awarded a EUR 550,000 Eurostars R&D grant.
GlycoMScan is excited to announce it has been awarded a EUR 550,000 Eurostars R&D grant.
In July a small group of international community members finished the first edition of the ‘Expat Program’ at Pivot Park. For 10 weeks they followed Dutch lessons followed with either Dutch culture training or group activities.
Official grant of €78.8 million for PharmaNL from the National Growth Fund
On July 12, it was announced by the National Growth Fund that PharmaNL has met the conditions to convert the conditional award of €78.8 million to a final grant.
For the second time, Pivot Park is hosting one of the Radboud Summer School courses on our campus.
Glycostem 15-year anniversary.
Glycostem has been making changes in the life of cancer patients and their families for the past 15 years and will continue to do so in the future.
Project Panther has reached it’s highest point
Both the Pivot Park and Heijmans flags have been raised and can now be seen waving in the wind on top of the Panther building.
Synaffix open-access manuscript published in MAbs.
Synaffix’s most recent open-access manuscript covering a 360° insight into their GlycoConnect technology for best-in-class ADCs is now published in MAbs!.
Glycostem announces new data presentation highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia
CEO RiboPro elected most promising entrepreneur of the year.
Sander van Asbeck, CEO and co-founder of RiboPro has been elected most promising entrepreneur of the year 2022. With his company, he develops messenger RNA technology for the development of new medical treatments.
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs.
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs.
Oss and Montreal, February 14, 2022. InProcess-LSP and Spectra Research Corporation (SRC) are pleased to announce they have entered into a partnership, combining SRC’s industry-leading market knowledge with InProcess’s world class and groundbreaking nanoparticle sizing technology delivering unique solutions for the particle characterization markets.
Pivot Park –
Gebouw RK
Kloosterstraat 9
5349 AB Oss
the Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Gebouw OP
Kloosterstraat 9
5349AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
